Shares of Hims & Hers Health Inc. (HIMS) plummeted by 8.45% on Thursday morning, as concerns arose over the company's ability to maintain its weight-loss offerings if the shortage of GLP-1 drugs, a popular weight-loss medication, comes to an end.
According to analysts at TD Cowen, who recently met with Hims & Hers management, the company believes it can provide a variety of weight-loss solutions, including oral medications, personalized dosages of compounded GLP-1s, branded GLP-1s, and liraglutide, which could ultimately be more affordable than traditional GLP-1 programs.
However, investors appear to be skeptical about the company's ability to maintain its weight-loss platform's growth trajectory if it can no longer offer compounded GLP-1 drugs, which have been in high demand due to the FDA's shortage list.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。